# BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

> **NCT01305551** · PHASE1 · WITHDRAWN · sponsor: **AstraZeneca**

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Saxagliptin
- **DRUG:** Metformin XR
- **DRUG:** Saxagliptin/Metformin XR FDC

## Key facts

- **NCT ID:** NCT01305551
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-03
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01305551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01305551, "BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01305551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*